Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 506-511

  Fleer, E A M ^a   Berkovic, D ^a   Grunwald, U ^a   Hiddemann, W ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Ether lysophospholipids; Hexadecylphosphocoline; Miltefosine; Miltefosine resistance

Indexed keywords

CHOLINE; EDELFOSINE; ILMOFOSINE; INOSITOL; MILTEFOSINE;

ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CHOLINE; DRUG RESISTANCE, NEOPLASM; HUMANS; INOSITOL; KB CELLS; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE;

EID: 0029994658     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00566-8     Document Type: Article

References (28)

1. Eibl H, Unger C. Hexadecylphosphocholine - a new and selective antitumor drug. Cancer Treat Rev 1990, 17, 233-242.
2. Fleer EAM, Kim D-J, Nagel GA, Eibl H, Unger C. Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma raji cells. Onkologie 1990, 13, 295-300.
3. Unger C, Fleer EAM, Kötting J, Neumüller W, Eibl H. Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. In Unger C, Hilgard P, Eibl H, eds. Progress in Experimental Tumour Research. Karger Verlag, Basel, 1992, 34, 25-32.
4. Hilgard P, Stekar J, Voegeli R, Harleman JH. Experimental therapeutic studies with miltefosine in rats and mice. In Unger C, Hilgard P, Eibl H, eds. Progress in Experimental Tumor Research. Karger Verlag, Basel, 1992, 34, 116-130.
5. Muschiol C, Berger MR, Schuler B, et al. Alkyl phosphocholines: toxicity and anticancer properties. Lipids 1987, 22, 930-934.
6. Unger C, Eibl H, Nagel GA, et al. Hexadecylphosphocholine in the topical treatment of skin metastases: a Phase I trial. Contrib Oncol 1989, 37, 219-223.
7. Dummer R, Röger J, Vogt T, et al. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. In Unger C, Hilgard P, Eibl H, eds. Progress in Experimental Tumor Research. Karger Verlag, Basel, 1992, 34, 160-169.
8. Ries UJ, Fleer EAM, Breiser A, et al. In vitro and in vivo antitumoral activity of alkylphosphonates. Eur J Cancer 1993, 29A, 96-101.
9. Überall F, Oberhuber H, Mali K, Zaknun J, Demuth L, Grunicke HH. Hexadecylphosphocholine inhibits phosphate formation and protein kinase C activity. Cancer Res 1991, 51, 807-812.
10. Shoji M, Raynor RL, Fleer EA, Eibl H, Vogler WR, Kuo JF. Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL 60 cells. Lipids 1991, 26, 144-149.
11. Berkovic D, Berkovic K, Fleer EAM, Eibl H, Unger C. Effects of hexadecylphosphocholine on cellular proliferation and PKC activity. Eur J Cancer 1994, 30A, 509-515.
12. Heesbeen EC, Verdonck LF, Staal GE, Rijksen G. Protein kinase C is not involved in the cytotoxic action of 1-octadecyl-2-O-methyl-sn-glycerol-3-phosphocholine in HL-60 and K562 cells. Biochem Pharmacol 1994, 47, 1481-1488.
13. Vehmeyer K, Scheurich P, Eibl H, Unger C. Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2. Cellular Immunol 1991, 136, 232-234.
14. Hochhuth C, Berkovic D, Eibl H, Unger C, Doenecke D. Effects of antineoplastic phospholipids on parameters of differentiation in U 937 cells. J Cancer Res Clin Oncol 1990, 116, 456-466.
15. Vehmeyer K, Eibl H, Unger C. Hexadecylphosphocholine stimulates the colony-stimulating factor-dependent growth of hematopoietic progenitor cells. Exp Hematol 1992, 20, 1-5.
16. Eibl H, Wooley P. Synthesis of enantiomerically pure glyceryl esters and ethers: I. Methods employing the precursor 1.2-isopropylidene-sn-glycerol. Chem Phys Lipids 1986, 41, 53-63.
17. Eibl H, Lands WE. A new, sensitive determination of phosphate. Anal Biochem 1969, 30, 51-57:
18. Hudson L, Hay FC. In Practical Immunology. Blackwell Scientific Publications, Oxford, 1976, 29-32.
19. Fleer EAM, Unger C, Kim D-J, Eibl H. Metabolism of ether phospholipids and analogs in neoplastic cells. Lipids 1987, 22, 856-861.
20. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37, 911-917.
21. Omodeo-Sale F, Marchesini S, Fishman PH, Berra B. A sensitive enzymatic assay for the determination of cholesterol in lipid extracts. Anal Biochem 1984, 145, 347-350.
22. Rustenbeck I, Lenzen S. Quantitation of hexadecylphosphocholine by high-performance thin-layer chromatography with densitometry. J Chromatogr 1990, 525, 85-91.
23. Kötting J, Marschner N, Neumuller W, Unger C, Eibl H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. In Eibl H, Hilgard P, Unger C, eds. Alkylphosphocholines: New Drugs in Cancer Therapy. Progress in Experimental Tumor Research. Karger, Basel, 1992, 34, 131-142.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193, 262-268.
25. Bensadoun A, Weinstein D. Assay of proteins in the presence of interfering materials. Anal Biochem 1976, 70, 241-250.
26. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977, 83, 346-356.
27. Hilgard P, Stekar J, Voegeli R, et al. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol 1988, 24, 1457-1461.
28. Rosen O, Schymanietz C, Hölzel F. Antiproliferative, cytotoxic and recovery effects in tumor cell cultures treated with synthetic phospholipids. Int J Oncol 1994, 5, 517-523.